World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
79
Citations
23074
World Ranking
17559
National Ranking
8784

Roberto Pili publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Roberto Pili sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 411 publications — 41st percentile

41% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Roberto Pili D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Roberto Pili sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 79 D-Index — 14th percentile

14% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Roberto Pili is affiliated with the University at Buffalo, State University of New York in the United States. Their research primarily spans the fields of Medicine and Biochemistry, Genetics and Molecular Biology, with a significant focus on several key subfields including Pulmonary and Respiratory Medicine, Oncology, Molecular Biology, Cancer Research, and Epidemiology.

Their work addresses a variety of main topics related to cancer biology and treatment, prominently featuring:

  • Renal cell carcinoma treatment
  • Prostate Cancer Treatment and Research
  • Head and Neck Cancer Studies
  • Epigenetics and DNA Methylation
  • Oral health in cancer treatment
  • Cancer Immunotherapy and Biomarkers
  • Histone Deacetylase Inhibitors Research

Roberto Pili has published extensively in several key venues, with frequent contributions in:

  • Journal of Clinical Oncology
  • Cancer Research
  • Geriatrics
  • Cancers
  • Annals of Oncology

The following are some selected recent papers authored or co-authored by Roberto Pili, revealing the scope of research interests and collaborations:

  • CDK12-Altered Prostate Cancer: Clinical Features and Therapeutic Outcomes to Standard Systemic Therapies, Poly (ADP-Ribose) Polymerase Inhibitors, and PD-1 Inhibitors, 2020, JCO Precision Oncology
  • Ageing and COVID-19: What Is the Role for Elderly People?, 2020, Geriatrics
  • Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma, 2023, Journal of Clinical Oncology
  • Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer, 2020, British Journal of Cancer
  • Pharmacological polyamine catabolism upregulation with methionine salvage pathway inhibition as an effective prostate cancer therapy, 2020, Nature Communications

Frequent co-authors of Roberto Pili include:

  • Poolakkad S. Satheeshkumar
  • Joel B. Epstein
  • Minu P. Mohan
  • Christopher Rupert
  • Донателла Рита Петретто

Best Publications

  • Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma

    Robert J. Motzer;Thomas E. Hutson;Piotr Tomczak;M. Dror Michaelson

  • A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor.

    A. Passaniti;R. M. Taylor;R. Pili;Y. Guo

  • Digoxin and other cardiac glycosides inhibit HIF-1α synthesis and block tumor growth

    Huafeng Zhang;David Z. Qian;Yee Sun Tan;Kang Ae Lee

  • Adjuvant Sunitinib or Sorafenib for High-Risk, Non-Metastatic Renal-Cell Carcinoma (ECOG-ACRIN E2805): A Double-Blind, Placebo-Controlled, Randomised, Phase 3 Trial

    Naomi B. Haas;Judith Manola;Robert G. Uzzo;Keith T. Flaherty

  • NCCN clinical practice guidelines in oncology: kidney cancer.

    Robert J Motzer;Neeraj Agarwal;Clair Beard;Graeme B Bolger

  • Consensus guidelines for the use and interpretation of angiogenesis assays

    Patrycja Nowak-Sliwinska;Kari Alitalo;Elizabeth Allen;Andrey Anisimov

  • Class II Histone Deacetylases Are Associated with VHL-Independent Regulation of Hypoxia-Inducible Factor 1α

    David Z. Qian;Sushant K. Kachhap;Spencer J. Collis;Henk M.W. Verheul

  • Lysosomal sequestration of sunitinib: a novel mechanism of drug resistance

    Kristy J. Gotink;Henk J. Broxterman;Mariette Labots;Richard R. de Haas

  • Entinostat neutralizes myeloid derived suppressor cells and enhances the antitumor effect of PD-1 inhibition in murine models of lung and renal cell carcinoma

    Ashley Orillion;Ashley Orillion;Ayumi Hashimoto;Nur P Damayanti;Li Shen

  • Targeting tumor angiogenesis with histone deacetylase inhibitors : the hydroxamic acid derivative LBH589

    David Z. Qian;Yukihiko Kato;Shabana Shabbeer;Yongfeng Wei

  • The histone deacetylase inhibitor NVP-LAQ824 Inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584

    David Z. Qian;Xiaofei Wang;Sushant K. Kachhap;Yukihiko Kato

  • Targeting tumor angiogenesis with histone deacetylase inhibitors.

    Leigh Ellis;Hans Hammers;Roberto Pili

  • Kidney cancer, version 3.2015: Featured updates to the NCCN guidelines

    Robert J. Motzer;Eric Jonasch;Neeraj Agarwal;Clair Beard

  • The α-Glucosidase I Inhibitor Castanospermine Alters Endothelial Cell Glycosylation, Prevents Angiogenesis, and Inhibits Tumor Growth

    Roberto Pili;Joan Chang;Richard A. Partis;Richard A. Mueller

  • Id1 regulates angiogenesis through transcriptional repression of thrombospondin-1

    Olga V Volpert;Roberto Pili;Hashmat A Sikder;Thomas Nelius

  • VEGF165 Expressed by a Replication-Deficient Recombinant Adenovirus Vector Induces Angiogenesis In Vivo

    Judith Mühlhauser;Marsha J. Merrill;Roberto Pili;Hiroyuki Maeda

  • A Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Hormone-Refractory Metastatic Prostate Cancer

    Elisabeth I. Heath;David W. Hillman;Ulka Vaishampayan;Shijie Sheng

  • Targeting Vascular Endothelial Growth Factor for Relapsed and Refractory Adult Acute Myelogenous Leukemias: Therapy with Sequential 1-β-d-Arabinofuranosylcytosine, Mitoxantrone, and Bevacizumab

    Judith E. Karp;Judith E. Karp;Ivana Gojo;Roberto Pili;Christopher D. Gocke

  • The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival and overall survival of patients treated with sunitinib for metastatic renal cell carcinoma.

    Daniel Keizman;Maya Ish-Shalom;Peng Huang;Mario A. Eisenberger

  • Kidney cancer, version 1.2021: Featured updates to the nccn guidelines

    Robert J. Motzer;Eric Jonasch;Shawna Boyle;Maria I. Carlo

Frequent Co-Authors

Michael A. Carducci
Michael A. Carducci Johns Hopkins University
Li Shen
Li Shen Icahn School of Medicine at Mount Sinai
Mario A. Eisenberger
Mario A. Eisenberger Johns Hopkins University
Walter M. Stadler
Walter M. Stadler University of Chicago
Andrew J. Armstrong
Andrew J. Armstrong Duke University
Liang Cheng
Liang Cheng Brown University
Toni K. Choueiri
Toni K. Choueiri Harvard University
Emmanuel S. Antonarakis
Emmanuel S. Antonarakis University of Minnesota
Michael J. Morris
Michael J. Morris Memorial Sloan Kettering Cancer Center
Robert J. Motzer
Robert J. Motzer Memorial Sloan Kettering Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in healthcare careers beyond traditional medical school, there are a variety of accessible and affordable online degree options in the United States. Online programs have become increasingly popular, offering flexibility for working professionals and non-traditional students.

Nursing is one of the fastest-growing fields in healthcare, and there are many educational pathways to consider. If you already hold an RN license, you can enhance your qualifications by completing an rn to bsn cheapest program online. These programs are often both cost-effective and convenient, allowing you to advance your career.

If you’re aiming for advanced practice or leadership, pursuing online nursing phd programs can open new opportunities in research and teaching. For those with non-nursing backgrounds, cheapest direct entry msn programs offer a fast track to becoming a registered nurse.

If you’re just starting out and are concerned about admission requirements, consider exploring easy nursing programs to get into. This can help you begin your healthcare career without unnecessary barriers.

Best Scientists Citing Roberto Pili

Trending Scientists

Recently Published Articles